Clinical trial · Observational
Impact of Catch-up HPV Vaccination
Impact of Catch-up HPV Vaccination on the Development of Cervical Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): overestimation of the number of healthcare professionals participating in the inclusions
Summary
Brief summary (as posted)
Each year in France, more than 6000 new cases of HPV inducted cancers are recorded. The vaccinal cover stays insufficient since less than 30% of the french population is vaccinated. Therefore french studies about vaccine efficacy and especially about the catch-up vaccine (done after 15years old) are needed. HPVAC2 is a prospective, analytic and monocentric study designed to learn the impact of the catch-up HPV vaccination. Women from 25 years old and born after 1984 may be included if they come to the Brest CHU to do their regular cervical smear. At this time, a survey will be given to know their vaccinal status. The aim of the study is to prove the efficacy of the catch up vaccination by analyzing the cervical smears results and by comparing the vaccinated group with the not-vaccinated group.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Cervical Lesion | — | UNRESOLVED | — |
| HPV | — | UNRESOLVED | — |
| HPV Vaccination | — | UNRESOLVED | — |
| Vaccine Preventable Disease | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Vaccinated
- description
- Patients who have been vaccinated against HPV virus.
- label
- Not vaccinated
- description
- Patients who have not been vaccinated against HPV virus.
Primary outcomes (1)
- measure
- Test HPV and smear test result.
- timeFrame
- 13 months.
- description
- Study the effectiveness of anti-HPV vaccine (done between 15 and 19 years old).
Secondary outcomes (4)
- measure
- Test HPV and smear test result.
- timeFrame
- 13 months.
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 38 Years
Show eligibility criteria text
Inclusion Criteria: * Age limit * Patient must have done a HPV or smear test during the study period * Consent necessary Exclusion Criteria: * Age limit * No HPV or smear test done in the study period * Patient not able to give her consent
References
Publications (0)
Data not yet available